Eli Lilly and Company (NYSE:LLY) Holdings Lowered by Intrust Bank NA

Intrust Bank NA reduced its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 3.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,941 shares of the company's stock after selling 414 shares during the period. Eli Lilly and Company comprises about 1.0% of Intrust Bank NA's holdings, making the stock its 22nd largest holding. Intrust Bank NA's holdings in Eli Lilly and Company were worth $9,990,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Principal Financial Group Inc. raised its stake in Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after buying an additional 60,306 shares in the last quarter. Fiduciary Trust Co lifted its stake in Eli Lilly and Company by 6.5% during the third quarter. Fiduciary Trust Co now owns 8,561 shares of the company's stock worth $7,584,000 after purchasing an additional 522 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in Eli Lilly and Company by 0.9% in the third quarter. Hantz Financial Services Inc. now owns 17,961 shares of the company's stock valued at $15,912,000 after purchasing an additional 155 shares in the last quarter. Carl P. Sherr & Co. LLC increased its stake in Eli Lilly and Company by 0.4% in the third quarter. Carl P. Sherr & Co. LLC now owns 5,526 shares of the company's stock valued at $4,896,000 after purchasing an additional 24 shares during the last quarter. Finally, CWS Financial Advisors LLC raised its holdings in Eli Lilly and Company by 7.3% during the third quarter. CWS Financial Advisors LLC now owns 1,200 shares of the company's stock worth $1,063,000 after purchasing an additional 82 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Activity

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,840 shares in the company, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Bank of America reaffirmed a "buy" rating and issued a $997.00 target price on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Berenberg Bank set a $970.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, January 16th. Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research report on Friday, January 17th. Finally, Citigroup cut their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research report on Tuesday, January 28th. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $1,009.72.

Eli Lilly and Company Stock Down 1.3 %

Shares of Eli Lilly and Company stock traded down $10.65 on Tuesday, hitting $815.26. 1,003,187 shares of the company's stock traded hands, compared to its average volume of 3,617,458. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The firm's 50-day moving average is $846.30 and its 200 day moving average is $835.00. The stock has a market cap of $773.01 billion, a P/E ratio of 69.59, a PEG ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its Board of Directors has authorized a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to reacquire up to 2% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's leadership believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.